ERBB2 and breast carcinoma: A phase 3 randomized controlled trial found similar disease progression and incident treatment-related adverse events and cardiotoxicity among patients with HER2+ early breast cancer receiving trastuzumab biosimilar Herzuma compared to Herceptin [10].